JCEM：青少年胰岛素增敏治疗可预防成年特异性过多的表型

EE-CA和PioFluMet化疗当中和化疗后CRP、CIMT、胃脂肪酸和MSI变化

用药雌ACS是极少女睾酮可避免的标准规范化疗，即使当这些女孩子没有早产的安全性。为了更为皮质醇与抗生素增敏化疗打压非成年人青极少年，在化疗当中和化疗后对睾酮可避免的因素，来自巴萨罗那的大学Sant Joan de Deu医院内分泌科的Lourdes Ibanez任教及其团队进行了一项数据分析，该数据分析发现青极少年抗生素增敏化疗打压不太可能预防措施未成年部份睾酮可避免表型式。该数据分析结果在线发表文章在2012年4年底1日的英国《临床内分泌降解杂志》（The journal of clinical endocrinology & metabolism）上。该数据分析是一项随机非盲试验，人脑是高抗生素胆固醇和睾酮可避免的非成年人极少女，且没有早产的安全性（34例；平均年龄16岁；体重指数：23kg/m2）。数据分析更为炔雌醇醋酸环丙皮质醇（EE-CA）与小剂量芳基列酮（7.5mg/d）、氮他米特（62.5mg/d）和二甲双胍（850mg/d）联合（PioFluMet）化疗18个年底的。化疗后随访6年底。精确测量睾酮可避免（多毛症、痤疮分数和血清睾酮），诱导后抗生素，循环C重排蛋白质，颈动脉内膜当中层厚度，身体构成（吸**确测量法），腹部脂肪酸两区（磁共振成像）和年底经周期。该数据分析结果表明，EE-CA和PioFluMet同样缓解睾酮可避免，但有差异，以致因素其他结果。化疗后6个年底，PioFluMet化疗的女孩子比EE-CA化疗的女孩子有不够低的诱导后抗生素，不够低的C重排蛋白质低水平和不够裹的内膜当中层，并且他们的胃脂肪酸较极少，很强不够高的瘦体重，以及不够不太可能有规律的年底经周期。该数据分析发现，在非成年人的睾酮可避免的青极少年，PioFluMet化疗当中和化疗后的比皮质醇的好。打压依靠青极少年睾酮可避免的增大因素化疗后的表型式。在青极少年，PioFluMet相似的打压不太可能预防措施未成年部份睾酮可避免的表型式，还包括成年人和身体健康低下。与冠心病相关的持续发展读到：

Diabetes Care：冠心病与心衰病患心脏外周活性增大相关Diabetes Care：lixisenatide有效率改善二甲双胍压制不佳的2型式冠心病群体的浓度2013 NIH 早产期冠心病(GDM)诊断发表文章声明JAMA：褪黑激素分泌减极少提高II型式冠心病安全性DIABETES CARE：空腹浓度筛查早产冠心病添新证Eur J Endocrinol: 1型式冠心病病患HbA1c低水平过高能从外部避免抑郁不够多信息请点击：有关冠心病不够多资料

Oral Contraception vs Insulin Sensitization for 18 Months in Nonobese Adolescents With Androgen Excess: Posttreatment Differences in C-Reactive Protein, Intima-Media Thickness, Visceral Adiposity, Insulin Sensitivity, and Menstrual Regularity BackgroundAn oral estro-progestagen is the standard medication given to adolescent girls with androgen excess, even when those girls are not at risk of pregnancy. AimThe aim of this study was to compare on-treatment and post-treatment effects of intervention with an oral contraceptive vs an insulin-sensitizing treatment for androgen excess in nonobese adolescents. DesignThis was a randomized, open-label trial. Study PopulationSubjects were nonobese adolescent girls with hyperinsulinemic androgen excess and without risk of pregnancy (mean age, 16 years; body mass index, 23 kg/m2; n = 34). InterventionsThe effects of treatment with ethinylestradiol-cyproteroneacetate (EE-CA) vs a low-dose combination of pioglitazone (7.5 mg/d), flutamide (62.5 mg/d), and metformin (850 mg/d) (PioFluMet) for 18 months were studied. Posttreatment follow-up was for 6 months. Main Outcome MeasuresAndrogen excess (hirsutism and acne scores and serum testosterone), glucose-stimulated insulinemia, circulating C-reactive protein, carotid intima media thickness, body composition (absorptiometry), abdominal fat partitioning (magnetic resonance imaging), and menstrual regularity were measured. ResultsEE-CA and PioFluMet attenuated androgen excess similarly but had divergent, and even opposing, effects on other outcomes. Six months posttreatment, the PioFluMet-treated girls had a lower glucose-induced insulinemia, a lower C-reactive protein level, and a thinner intima media than the EE-CA–treated girls, and they were viscerally less adipose, had a higher lean mass, and were more likely to he regular cycles. ConclusionsThe on-treatment and post-treatment effects of PioFluMet compared forably with those of oral contraception in nonobese adolescents with androgen excess. The intervention whereby androgen excess is reduced in adolescence influences the post-treatment phenotype. PioFluMet-like interventions in adolescence may thus hold the potential to prevent part of the androgen-excess phenotype in hood, including adiposity and subfertility.